Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (111)

I-001Noha Abdelgawad

Pharmacokinetic Modelling of Rifampicin, Isoniazid, Pyrazinamide, and Linezolid in Central Nervous System: Insights from a Rabbit Model of Tuberculosis Meningitis

Wednesday 10:20-11:50

I-002Kimberly Adams

Physiologically-Based Pharmacokinetic Modeling of Extended-Release MK-2048 Formulations for HIV Pre-Exposure Prophylaxis in Non-Human Primates

Wednesday 10:20-11:50

I-003Katrine Agergaard

Population pharmacokinetic modelling of whole blood and intracellular tacrolimus in adult kidney transplanted patients

Wednesday 10:20-11:50

I-004Jurij Aguiar Zdovc

Population pharmacokinetic-pharmacodynamic analysis of elafibranor and metabolite GFT1007 to support exposure-response characterization and dose selection in patients with primary biliary cholangitis

Wednesday 10:20-11:50

I-005Ludovica Aiello

Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator

Wednesday 10:20-11:50

I-006Karam Alali

Population pharmacokinetic Models of regular SC insulin for hyperglycemia following acute ischemic stroke among patients with and without pre-existing diabetes mellitus

Wednesday 10:20-11:50

I-007Mahmoud Ali

mastering upset plots: a comprehensive tutorial for effective data visualization in pharmacometrics and drug development

Wednesday 10:20-11:50

I-008Nikolaos Alimpertis

Leveraging the Finite Absorption Time (F.A.T.) Concept for Advancing PBPK Modeling and Pharmacometric structural models: Moving MIDD to Model Informed Drug Development and Assessment (MIDDA)

Wednesday 10:20-11:50

I-009Magali Amiel

Physiologically Based Pharmacokinetic modelling of the Drug-Drug Interaction between Ivacaftor and Lefamulin in Cystic Fibrosis patients

Wednesday 10:20-11:50

I-010Karkhanis Aneesh

A PBPK model of 4β-hydroxycholesterol, an endogenous biomarker for hepatic CYP3A activity.

Wednesday 10:20-11:50

I-011Arkadiusz Adamiszak

Do critically ill patients undergoing continuous renal replacement therapy require ceftaroline dosage adjustments? Ceftaroline PopPK model and dosage simulations with probability of target attainment analysis based on retrospective data.

Wednesday 10:20-11:50

I-012Innocent Asiimwe

The Applied Pharmacometrics Training Program – Year 3 Sustainability

Wednesday 10:20-11:50

I-013Romain Aubry

Translational PKPD modelling of ceftazidime/avibactam for treatment of carbapenemase-producing Klebsiella pneumoniae in the persistently neutropenic rabbit pneumonia model

Wednesday 10:20-11:50

I-014Sally Babiker

Dose rationale for bedaquiline in paediatric patients with multi drug-resistant tuberculosis

Wednesday 10:20-11:50

I-015Salma Bahnasawy

Applying PKPD modelling to evaluate the impact of plasma proteins in time-kill experiments; does the protein binding matter?

Wednesday 10:20-11:50

I-016Giammarco Baiardi

population pharmacokinetics and dose rationale for deferasirox in the treatment of iron overload in paediatric patients undergoing hematopoietic stem cell transplantation

Wednesday 10:20-11:50

I-017Pavel Balazki

User-friendly and Quality-Controlled PBPK/QSP M&S Framework in R for Regulatory Submissions using Open Systems Pharmacology Software

Wednesday 10:20-11:50

I-018Asma Baliouze

Exposure-Response Analysis of Centanafadine Sustained Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder

Wednesday 10:20-11:50

I-019Annabelle Ballesta

Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study

Wednesday 10:20-11:50

I-020Irina Baltcheva

Do more with less: Model-informed dosing rationale of iptacopan in paroxysmal nocturnal hemoglobinuria (PNH)

Wednesday 10:20-11:50

I-021Enrique José Bandín Vilar

OPTIMIZATION OF THE DOSAGE REGIMEN OF LONG-ACTING INJECTABLE ARIPIPRAZOLE THROUGH MONTE CARLO SIMULATIONS

Wednesday 10:20-11:50

I-022Jeff Barrett

Open-science solutions enabled within a digital research environment to support MIDD (Model Informed Drug Development) and precision dosing

Wednesday 10:20-11:50

I-023Imke Bartelink

Enabling Tyrosine Kinase Inhibitor Precision Medicine through PET-Guided Physiologically-Based Pharmacokinetic Modeling

Wednesday 10:20-11:50

I-024Carla Bastida Fernández

Predictive performance of published meropenem population pharmacokinetic models in critically ill adult patients.

Wednesday 10:20-11:50

I-025Maxime Beaulieu

Evusheld hastens viral clearance in COVID-19 hospitalized patients: a modeling analysis of the randomized DisCoVeRy trial

Wednesday 10:20-11:50

I-026Emily Behrens

External evaluation of pharmacometric models of moxifloxacin for Bayesian forecasting in the treatment of tuberculosis

Wednesday 10:20-11:50

I-027Massinissa Beldjenna

Development of a multi-endpoint mechanistic pharmacokinetic-pharmacodynamic model describing CD40 antagonism in autoimmune diseases.

Wednesday 10:20-11:50

I-028Salih Benamara

Development of a PBPK model to predict monoclonal antibody pharmacokinetics and bioavailability following subcutaneous administration

Wednesday 10:20-11:50

I-029Amina Bensalem

Concentration-effect relationship of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in healthy Beagle dogs

Wednesday 10:20-11:50

I-030Martin Bergstrand

A workflow for evaluating and optimizing the designs of paediatric studies

Wednesday 10:20-11:50

I-031Jan Berkhout

A model-based approach to predict SC administration and free target dynamics for monoclonal antibodies using PK and total target measurements after IV administration

Wednesday 10:20-11:50

I-032Monir Bertayli

PK-PD model of morphine, pregabalin and their combination to assess the opioid-sparing effect

Wednesday 10:20-11:50

I-033Daniele Boaretti

Towards an integrated mPBPK/PD model for drug-optimization and prediction of relapse after treatment of tuberculosis in mice

Wednesday 10:20-11:50

I-035Rolien Bosch

From In Vitro Efficacy to Long-term HbA1c Response for GLP-1R/GlucagonR Agonism using the 4GI-HbA1c Systems Model

Wednesday 10:20-11:50

I-036Chloé Bracis

Mechanisms of ART-free virus control of SHIV with AAV gene therapy delivery of eCD4Ig

Wednesday 10:20-11:50

I-037Dominic Bräm

Implementation of neural ordinary differential equations in the pharmacometric software packages Monolix, NONMEM, and nlmixr

Wednesday 10:20-11:50

I-038Myriam Briki

Model-based meta-analysis of individual patient data from three independent datasets for the characterization of intravenous 5-fluorouracil population pharmacokinetics

Wednesday 10:20-11:50

I-039Anne Brochot

Comparison of common methodologies for accounting for IIV for oral bioavailability in the absence of intravenous data

Wednesday 10:20-11:50

I-040Jordan Brooks

Steps Toward Model-Informed Precision Dosing of PEG-Asparaginase in Children and Young Adults

Wednesday 10:20-11:50

I-041Divya Brundavanam

Addressing Confounding Bias in Exposure-Response Analysis: Evaluating Instrumental Variable Modeling Strategies

Wednesday 10:20-11:50

I-042Divakar Budda

A comprehensive binding kinetic model for morphine in the pain matrix regions: what are the most important physiological factors for morphine µ-OR occupancy?

Wednesday 10:20-11:50

I-043Nils Bundgaard

Model informed dose projection for SAB-176 using a joint time-to-event modeling approach in high-risk (HR) patients infected with Influenza

Wednesday 10:20-11:50

I-044Nils Bundgaard

Framework for Polyclonal Antibody Drug Development: Integrating Trial Data and Literature Models

Wednesday 10:20-11:50

I-045Nils Bundgaard

Characterization of the population dose-exposure-efficacy relationships of vamorolone, a synthetic corticosteroid drug in the treatment of Duchenne Muscular Dystrophy (DMD)

Wednesday 10:20-11:50

I-046Andrew Butler

Predicting the effect of postpartum changes in breastmilk composition on the partitioning of anti-malarial medications

Wednesday 10:20-11:50

I-047Andrew Butler

Exploration of CPRD and Yellow Card real-world data to support efficacy and safety targets for levonorgestrel contraceptives.

Wednesday 10:20-11:50

I-048Jose Miguel Calderin Miranda

Population pharmacokinetic analysis of isoniazid in plasma and cerebrospinal fluid from adults with HIV-associated tuberculosis meningitis

Wednesday 10:20-11:50

I-049Elio Campanile

Supporting the development and optimization of mRNA-encoded therapeutics through a multiscale Physiologically Based Pharmacokinetic (PBPK) platform

Wednesday 10:20-11:50

I-050Kangna CAO

A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages

Wednesday 10:20-11:50

I-051Zhihai Cao

Evaluating Drug Interactions Between Ritonavir and Hydrocodone: Implications From Physiologically Based Pharmacokinetic Simulation

Wednesday 10:20-11:50

I-052Bibiana CARDOZO

PKPD Relationship between THC Levels and Self-Assessment of Driving Proficiency Among Cannabis Users

Wednesday 10:20-11:50

I-053Adriana Castiñeiras

Population analysis of the in vivo pharmacokinetic characteristics of a letrozole sustained delivery formulation in Beagle dogs

Wednesday 10:20-11:50

I-054Daniel Centanni

Pharmacometric modeling to capture the time varying pharmacokinetics of PEG-asparaginase in acute lymphoblastic leukemia: A multi-protocol analysis from Nordic and Baltic countries

Wednesday 10:20-11:50

I-055Maddalena Centanni

Population pharmacodynamic characterization of automatically classified circulating tumor cells and vesicles and their relationship to survival in metastatic colorectal cancer patients

Wednesday 10:20-11:50

I-056Marc Cerou

A novel drug disease model in oncology to evaluate benefit-risk balance of tusamitamab ravtansine monotherapy

Wednesday 10:20-11:50

I-057Anne Chain

Population Pharmacokinetic and Exposure Response Analysis of Belzutifan in Advanced Renal Cell Carcinoma

Wednesday 10:20-11:50

I-059Akshita Chawla

Comparative assessment of incretin therapies on weight loss through a model-based meta-analysis approach

Wednesday 10:20-11:50

I-060Wenjun Chen

Physiologically based pharmacokinetic modeling of TLL-018 for prediction of human pharmacokinetics and in vitro-in vivo extrapolation

Wednesday 10:20-11:50

I-061Lu Chen

Time-dependent pharmacokinetics of hydromethylthionine mesylate (HMTM), a tau aggregation inhibitor, in healthy volunteers and patients with Alzheimer’s Disease

Wednesday 10:20-11:50

I-062Chengcong CHEN

Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer

Wednesday 10:20-11:50

I-063Marylore Chenel

Physiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation in the treatment of cryptococcal meningoencephalitis.

Wednesday 10:20-11:50

I-064Limei Cheng

Using machine learning to predict longitudinal platelet counts: a methodology framework

Wednesday 10:20-11:50

I-065Yi-Han Chien

Modelling framework to simulate phenotypic results of antiviral PROTACs

Wednesday 10:20-11:50

I-066Maxwell Chirehwa

Designing Phase II studies for optimal Phase III dosing/regimen selection using end-to-end DETER modelling

Wednesday 10:20-11:50

I-067Heather Collis

A case study of applying machine learning to improve non-invasive assessment of fibrosis stage in MASLD

Wednesday 10:20-11:50

I-068Emmanuelle Comets

Modelling the dynamics of bacterial colonisation in a murine model of Urinary Tract Infections

Wednesday 10:20-11:50

I-069Léa COMIN

Modelling the whole-body pharmacokinetics (WBPK) of radiolabeled glyburide in healthy volunteers

Wednesday 10:20-11:50

I-070Craig Comisar

Population pharmacokinetic modeling to support dose selection of zavegepant nasal spray in pediatrics.

Wednesday 10:20-11:50

I-071Bárbara Costa

Pharmacokinetic Simulation Study: Exploring Lamotrigine’s Impact Across Diverse Patient Populations

Wednesday 10:20-11:50

I-073Perrine Courlet

Unlocking efficiency in dose selection based on pharmacokinetic-pharmacodynamic modeling of tumor size data: Insights from Clinical Trial Simulations

Wednesday 10:20-11:50

I-074Marina Cuquerella Gilabert

Impact of sampling procedure on individual pharmacokinetic parameter estimation methods

Wednesday 10:20-11:50

I-075Liu Dan

Population pharmacokinetics modeling of selpercatinib and simulation to support posology in paediatric and adolescent patients

Wednesday 10:20-11:50

I-076Alessandro De Carlo

PopPK-PD modelling of Carboplatin-induced myelosuppression to support therapeutic drug monitoring and dose individualization in cancer patients using Electronic Health Record Data

Wednesday 10:20-11:50

I-077Miné De Kock

Semi-mechanistic PK model development of Sabestomig for Dose Selection

Wednesday 10:20-11:50

I-078Robert de Mooij

A quantitative comparison of tumor sub-model variants in a minimal PBPK model for early clinical dose projections of antibody therapeutics in oncology

Wednesday 10:20-11:50

I-079Giuseppe De Nicolao

A mixed effect multi-funnel model for country surveillance of antibiotic resistance: evidence from the WHO GLASS dashboard

Wednesday 10:20-11:50

I-081Kristof De Vos

In vitro-in silico platform for mechanistic investigation of bile acid disposition in cultured hepatocytes

Wednesday 10:20-11:50

I-082Wilbert de Witte

In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models

Wednesday 10:20-11:50

I-083Oleg Demin

Exploring strategies to enhance DNAM1 signaling and inhibit the TIGIT/PVRIG axis

Wednesday 10:20-11:50

I-084Oleg Demin Jr

Optimizing first-in-human dose for HPN536, a T-Cell Engager Targeting Mesothelin: comparison of MABEL PK-driven approach and mechanistic translational PK/RO/PA modeling

Wednesday 10:20-11:50

I-085Abdallah Derbalah

Beyond the Liver; In Silico Screening for Tissue-Specific Oligonucleotide Delivery Receptors

Wednesday 10:20-11:50

I-086Laure Deyme

Population pharmacokinetic analysis of eliglustat in pediatric patients with Gaucher disease

Wednesday 10:20-11:50

I-087Alessandro Di Deo

Model-based evaluation of predictive markers of response to adalimumab in juvenile idiopathic arthritis

Wednesday 10:20-11:50

I-088Giovanni Di Veroli

Bridging the gap between secondary pharmacology and hemodynamics findings via Quantitative Systems modelling

Wednesday 10:20-11:50

I-089Nada Dia

Model-informed comparison of the clinical relevance of four renal function markers on meropenem target attainment in critically ill septic patients

Wednesday 10:20-11:50

I-090Cheikh Diack

Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema

Wednesday 10:20-11:50

I-091Ricardo Diaz de Leon Ortega

Modelling and simulation of the effect of a permeability enhancer on the absorption of a poorly permeable compound

Wednesday 10:20-11:50

I-093Aris Dokoumetzidis

Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modeling

Wednesday 10:20-11:50

I-094Vito Dozio

Population PK and exposure-response modeling to support the design of trials with Debio 0123, a WEE1 inhibitor, in cancer patients

Wednesday 10:20-11:50

I-095Vincent Duval

Pharmacokinetic/Pharmacodynamic framework to support the subcutaneous dosing regimen of nemolizumab in subjects with moderate-to-severe atopic dermatitis.

Wednesday 10:20-11:50

I-096Yin Edwards

Pharmacokinetics/pharmacodynamics and exposure-response modelling of VH3810109 (N6LS) in antiretroviral therapy-naïve adults with HIV-1 from the Phase IIa BANNER Study

Wednesday 10:20-11:50

I-097Jeroen Elassaiss-Schaap

Construction of IMPRES-M, a non-parametric impulse-response modeling method, in the context of varying pharmacokinetic profiles

Wednesday 10:20-11:50

I-098Omar Elkayal

Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis

Wednesday 10:20-11:50

I-099Ruben Faelens

Real-world data can estimate pre-exposure prophylactic drug effect in community-acquired respiratory infection trials

Wednesday 10:20-11:50

I-100Xiaoqing Fan

A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron

Wednesday 10:20-11:50

I-101Alan Faraj

Model-based approaches to prospectively power pediatric pharmacokinetic trials with limited sample size

Wednesday 10:20-11:50

I-102Ali Farnoud

A Neural Networks-assisted NLME Framework: Case Study on Modeling Platelet Counts

Wednesday 10:20-11:50

I-103Aneeq Farooq

A pharmacometric model assessing the synergistic effect of bacteriophage-polymyxin combination therapy in a clinical multidrug-resistant K. pneumoniae isolate in vitro.

Wednesday 10:20-11:50

I-104Aaqilah Fataar

Using Bayesian Modelling to Evaluate the Effect of a Neonatal Vancomycin Loading Dose on Therapeutic Target Attainment in a Low-Middle Income Country

Wednesday 10:20-11:50

I-105Floris Fauchet

Pharmacokinetic/Pharmacodynamic framework to support the subcutaneous dosing regimen of nemolizumab in subjects with Prurigo Nodularis

Wednesday 10:20-11:50

I-106Lucie FAYETTE

Using Fisher Information Matrix to predict covariate effects in forest plots and power of their relevance

Wednesday 10:20-11:50

I-107Denise Feick

How can we inform human intestinal permeability with Caco-2 permeability using PK-Sim®?

Wednesday 10:20-11:50

I-108Rebekka Fendt

A virtual ulcerative colitis patient population to explore combination treatments in in silico clinical trials

Wednesday 10:20-11:50

I-109Matthew Fidler

nlmixr2, rxode2 and Monolix: interchangeable models using monolix2rx and babelmixr2

Wednesday 10:20-11:50

I-110Sophie Fischer-Holzhausen

Development of a gestational Physiologically Based Kinetic model to predict rat dam and fetus exposure in PK-Sim/MoBi

Wednesday 10:20-11:50

I-111Nuria Folguera-Blasco

Coupling Quantitative Systems Pharmacology (QSP) and ML/AI: a story of pAIns and gAIns

Wednesday 10:20-11:50

I-112Thomas Frank

Automating pharmacometrics reporting using R Markdown

Wednesday 10:20-11:50

I-113Aline Fuchs

Human dose prediction approach for a therapeutic monoclonal antibody for a CNS indication inferred using preclinical data including target occupancy

Wednesday 10:20-11:50

I-114Laura Fuhr

Physiologically based pharmacokinetic modeling of amitriptyline and its active metabolite nortriptyline to investigate CYP2D6 and CYP2C19 mediated drug-drug and drug-gene interactions

Wednesday 10:20-11:50

I-115Gastón García Orueta

Population pharmacokinetics of teicoplanin in critically ill children undergoing continuous kindey replacement therapy

Wednesday 10:20-11:50

I-116María García-Cremades

Predictors of treatment outcomes in children with rifampicin-resistant tuberculosis: a global individual patient data meta-analysis

Wednesday 10:20-11:50